Al­con takes a crack at multi­bil­lion-dol­lar dry eye mar­ket, picks up 2 drugs from Langer spin­out

Kala Phar­ma­ceu­ti­cals may have nev­er come close to the block­buster dreams it had for its dry eye dis­ease treat­ment, but Al­con wants to see if it can take the drug fur­ther.

Af­ter giv­ing com­mer­cial­iza­tion its best shot over the past few years, Kala de­cid­ed the mar­ket­ing game is not for it af­ter all. In­stead, it will sell both of its com­mer­cial eye drop prod­ucts — Ey­su­vis for dry eye dis­ease, and In­vel­tys for post-op­er­a­tive in­flam­ma­tion and pain fol­low­ing oc­u­lar surgery — to Al­con for $60 mil­lion in cash, plus an undis­closed amount of mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER